|Videos|June 2, 2023
Interview with BioVectra’s Marc Sauer at DCAT
Author(s)Biovectra
KEY LEARNING OBJECTIVES
- BIOVECTRA is a global CDMO with a 52 year history – and a one stop shop for our clients.
- Our growth, in recent years, has been explosive and we’ve made big moves into biologics in recent years. Our new mRNA and Biomanufacturing facility opens later this year and just adds one more capability to our menu.
- We are a trusted partner for our clients. Our tagline of “We Care” came from focus group with clients who have time and again chosen us over competitors because of the service we provide.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Why Pharma’s AI Agents Need Smaller, Domain-Specific Models First
2
Batch Certification for New Manufacturing Technologies: The Qualified Person Role in a Digital Environment
3
Immortal Dragons Will Help Etheros Target Aging and Related Diseases
4
BirchBioMed’s Idiopathic Pulmonary Fibrosis Treatment Receives Orphan Drug Designation
5
